Overview
- Legal name
- CASTLEVAX INC
- Registered location
- NEW YORK, NY, USA
- Website
- Company website ↗
- Primary NAICS
- 325414 — Biological Product (except Diagnostic) Manufacturing
- Latest award activity
- Mar 27, 2026
Read company summary
CASTLEVAX INC is associated with UEI FLZ6THBQ53N3 and CAGE 9M4Y5 in public federal records. AcornBids currently links 1 prime award totaling $8.3M in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as Research and Development in Biotechnology (except Nanobiotechnology). These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 325414 (Biological Product (except Diagnostic) Manufacturing). Its public SAM.gov registration lists NEW YORK, NY, USA.
At a glance
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Oct 25, 2026.
Business information
Public SAM.gov registration details.
- Legal name
- CASTLEVAX INC
- UEI
- FLZ6THBQ53N3
- CAGE
- 9M4Y5
- Registered address
- 101 AVENUE OF THE AMERICAS FL 3, NEW YORK, NY, 10013, USA
- Registration status
- Active
- Primary NAICS
- 325414 — Biological Product (except Diagnostic) Manufacturing
- SAM activation
- Sep 15, 2025
- Initial registration
- May 8, 2023
- Entity start
- Aug 5, 2021
- SAM updated
- Sep 15, 2025
- Registration expires
- Sep 15, 2026
- Fiscal year end
- Dec 31
- Place of incorporation
- DE, USA
Research brief
Source facts
- Loaded prime-award records link 1 awards and $8,294,985 in reported obligations to this legal entity. Source
- Recorded awards include Research and Development in Biotechnology (except Nanobiotechnology) (NAICS 541714); this classification is not proof of every company capability. Source
- An example award describes: DEVELOP A NEXT-GENERATION, MUCOSALLY DELIVERED, COVID-19 BOOSTER VACCINE CAPABLE OF ELICITING MUCOSAL IMMUNITY AND PROTECTING AGAINST SARS-COV-2 BREAKTHROUGH INFECTION AND TRANSMISSION Source
Federal award analysis
Net transaction obligations by federal fiscal period.
Reported transaction obligations by federal fiscal period; includes deobligations. Missing transactions are not estimated. Histories follow awards currently assigned to this recipient and may include transactions under an earlier recipient. Coverage: 1 of 1 selected awards. Select a period to explore its awards.
Funding change
Dated, valued transaction obligations in equal-length adjacent periods; missing records are unknown. Default: last completed federal fiscal year. Percentage is unavailable when the prior period has no positive reported obligations.
| Measure | Reported value |
|---|---|
| Current period | Oct 1, 2025 – Sep 30, 2026 |
| Current obligations | $0 |
| Prior period | Oct 1, 2024 – Sep 30, 2025 |
| Prior obligations | Not reported |
| Change | Not reported |
| Growth | Not comparable |
Where the work is performed
State tile map; darker tiles have larger absolute net obligations. Outlined tiles indicate net deobligations. Unshaded tiles have no reported transactions in this selection. Other locations appear in the table.
Agencies
| Category | Period obligations | Awards |
|---|---|---|
| Department of Health and Human Services | $0 | 1 |
Offices
| Category | Period obligations | Awards |
|---|---|---|
| BARDA - ASPR / DAAPPO / BARDA DCMA | $0 | 1 |
Naics
| Category | Period obligations | Awards |
|---|---|---|
| 541714 — Research and Development in Biotechnology (except Nanobiotechnology) | $0 | 1 |
Psc
| Category | Period obligations | Awards |
|---|---|---|
| AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT | $0 | 1 |
Vehicles
| Category | Period obligations | Awards |
|---|---|---|
| Unclassified | $0 | 1 |
States
| Category | Period obligations | Awards |
|---|---|---|
| NY | $0 | 1 |
Set Asides
| Category | Period obligations | Awards |
|---|---|---|
| NO SET ASIDE USED. | $0 | 1 |
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75A50123C00065DEVELOP A NEXT-GENERATION, MUCOSALLY DELIVERED, COVID-19 BOOSTER VACCINE CAPABLE OF ELICITING MUCOSAL IMMUNITY AND PROTECTING AGAINST SARS-COV-2 BREAKTHROUGH INFECTION AND… | Department of Health and Human Services | $8.3M | Sep 30, 2023 | Jan 31, 2025 |
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Sep 15, 2025 |
| Source loaded | Sep 19, 2026 |
| Initial registration | May 8, 2023 |
| Entity start | Aug 5, 2021 |
Registration classifications: Small Business. These are separate from the reported certificates above.
| Industry | Reported size status |
|---|---|
| 325414 — Biological Product (except Diagnostic) Manufacturing | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| JORI HORBERG | Government business | Contact method not published | SAM registration | Not available |
| REBECCA BYERS | Electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 325414 — Biological Product (except Diagnostic) Manufacturing
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
Disclosed relationships only. Missing records do not establish that a contractor has no partners. Ambiguous parent award identifiers are excluded.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit